Paper35533682
Targeted treatment options for the management of metastatic/persistent and recurrent cervical cancer.
Mutlu L and 3 others. Expert Rev Anticancer Ther, 2022. Cited by 24 papers, by iCite.
Cite this record
ConductScience Library. Targeted treatment options for the management of metastatic/persistent and recurrent cervical cancer. Papers, record 35533682. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35533682
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Targeted treatment options for the management of metastatic/persistent and recurrent cervical cancer.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Uterine Cervical Neoplasms | Major topic |
| Bevacizumab | |
| Female | |
| Humans | |
| Immunotherapy | |
| Neoplasm Recurrence, Local |
Source PubMed
Cited by18
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 24 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42766055 | Therapy resistance-related ncRNAs in cervical cancer: biomarkers and therapeutic targets. | Daru | 2026 | https://conductscience.org/library/papers/42766055 | PubMed |
| 42598864 | WTAP-Mediated m6A Modification of TXNDC5 mRNA Promotes Cervical Carcinogenesis. | Kaohsiung J Med Sci | 2026 | https://conductscience.org/library/papers/42598864 | PubMed |
| 40813953 | Research on the regulatory effects and mechanisms of YES1 on apoptosis and autophagy in cervical cancer cells. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40813953 | PubMed |
| 40667502 | Curcumin, EGCG and apigenin in cervical cancer: mechanistic insights and therapeutic potential. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40667502 | PubMed |
| 40434537 | Exploring program-cell death patterns to predict prognosis and sensitivity of cervical cancer immunotherapy via multi-omics analysis and clinical samples. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40434537 | PubMed |
| 40270962 | Epithelial and macrophage cell interaction in cervical cancer through single-cell RNA-sequencing and spatial analysis. | Front Immunol | 2025 | https://conductscience.org/library/papers/40270962 | PubMed |
| 40159879 | Research hotspots and trends in the field of immune checkpoint inhibitors (ICIs) for cervical cancer: A bibliometric study from 2014 to 2024. | Hum Vaccin Immunother | 2025 | https://conductscience.org/library/papers/40159879 | PubMed |
| 39921802 | Evaluating the benefits of immunotherapy in metastatic cervical cancer: an observational retrospective analysis. | Clin Transl Oncol | 2025 | https://conductscience.org/library/papers/39921802 | PubMed |
| 39856747 | METTL3-dependent DLG2 inhibits the malignant progression of cervical cancer by inactivating the Hippo/YAP signaling. | Hereditas | 2025 | https://conductscience.org/library/papers/39856747 | PubMed |
| 38970071 | M2-type tumor-associated macrophages upregulated PD-L1 expression in cervical cancer via the PI3K/AKT pathway. | Eur J Med Res | 2024 | https://conductscience.org/library/papers/38970071 | PubMed |
| 38903711 | Progress in the study of antibody-drug conjugates for the treatment of cervical cancer. | Front Oncol | 2024 | https://conductscience.org/library/papers/38903711 | PubMed |
| 38892393 | Unraveling Differences in Molecular Mechanisms and Immunological Contrasts between Squamous Cell Carcinoma and Adenocarcinoma of the Cervix. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38892393 | PubMed |
| 38449793 | Extracellular cancer‑associated fibroblasts: A novel subgroup in the cervical cancer microenvironment that exhibits tumor‑promoting roles and prognosis biomarker functions. | Oncol Lett | 2024 | https://conductscience.org/library/papers/38449793 | PubMed |
| 38372700 | M6A modification regulates tumor suppressor DIRAS1 expression in cervical cancer cells. | Cancer Biol Ther | 2024 | https://conductscience.org/library/papers/38372700 | PubMed |
| 38200479 | Identification of a new gene signature for prognostic evaluation in cervical cancer: based on cuproptosis-associated angiogenesis and multi-omics analysis. | Cancer Cell Int | 2024 | https://conductscience.org/library/papers/38200479 | PubMed |
| 37664056 | Clinical analysis of decision implementation by a multidisciplinary team in cervical cancer cases in Ganzhou, China. | Front Oncol | 2023 | https://conductscience.org/library/papers/37664056 | PubMed |
| 37060468 | Molecular mechanisms augmenting resistance to current therapies in clinics among cervical cancer patients. | Med Oncol | 2023 | https://conductscience.org/library/papers/37060468 | PubMed |
| 36980689 | Inhibition of IDH3α Enhanced the Efficacy of Chemoimmunotherapy by Regulating Acidic Tumor Microenvironments. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/36980689 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35533682
GET https://conductscience.org/api/papers/v1/35533682/authors